Danny Houtsma
Impact in
-
- Frailty in Older Adults
-
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 9
- Cancer Treatment and Pharmacology 3
- Colorectal Cancer Treatments and Studies 2
-
- Advanced Breast Cancer Therapies 4
- Co-authors
- Henk‐Jan Guchelaar (6 shared papers)Hans Gelderblom (7 shared papers)Loes E. Visser (2 shared papers)Frederiek van den Bos (4 shared papers)E.T.M. Hille (1 shared paper)Martina Kinzig (1 shared paper)Max Roessler (1 shared paper)Rolf H. H. Groenwold (1 shared paper)
- Journals
- Annals of Oncology (2 papers)Journal of Clinical Oncology (2 papers)Clinical Cancer Research (1 paper)BMJ Open (1 paper)Scientific Reports (1 paper)
- Partner nations
- NetherlandsUnited StatesBelgium
In The Last Decade
Danny Houtsma
16 papers receiving 98 citations
Peers
Comparison fields: 5 of 43
- Geriatrics and Gerontology 10
- Oncology 42
- Cancer Research 22
- Pulmonary and Respiratory Medicine 38
- Pharmacology 8
Countries citing papers authored by Danny Houtsma
This map shows the geographic impact of Danny Houtsma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danny Houtsma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danny Houtsma more than expected).
Fields of papers citing papers by Danny Houtsma
This network shows the impact of papers produced by Danny Houtsma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danny Houtsma. The network helps show where Danny Houtsma may publish in the future.
Co-authors
The 25 scholars most cited alongside Danny Houtsma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 19 | |
| 2 | 2021 | 15 | |
| 3 | 2009 | 14 | |
| 4 | 2022 | 11 | |
| 5 | 2012 | 11 | |
| 6 | 2022 | 6 | |
| 7 | 2023 | 4 | |
| 8 | 2022 | 3 | |
| 9 | 2021 | 3 | |
| 10 | 2024 | 3 | |
| 11 | 2021 | 3 | |
| 12 | Variable workup calls for guideline development for type 2A hereditary haemochromatosis. | 2018 | 2 |
| 13 | 2024 | 1 | |
| 14 | 2025 | 1 | |
| 15 | 2023 | 1 | |
| 16 | 2013 | 1 | |
| 17 | 2024 | 0 | |
| 18 | 2025 | 0 | |
| 19 | 2025 | 0 |
About Danny Houtsma
Danny Houtsma is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Genetics and Genetics, having authored 19 papers that have together received 98 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (4 papers), Advanced Breast Cancer Therapies (4 papers), Cancer Treatment and Pharmacology (3 papers), Estrogen and related hormone effects (3 papers), Colorectal Cancer Treatments and Studies (2 papers), Economic and Financial Impacts of Cancer (2 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Chemotherapy-related skin toxicity (2 papers). The work is most often cited by research in Geriatrics and Gerontology (10 citations), Oncology (42 citations), Cancer Research (22 citations), Pulmonary and Respiratory Medicine (38 citations) and Pharmacology (8 citations). Danny Houtsma has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Henk‐Jan Guchelaar, Hans Gelderblom, Loes E. Visser, Frederiek van den Bos, E.T.M. Hille, Martina Kinzig, Max Roessler, Rolf H. H. Groenwold, Henk Codrington and Rieneke T. Lugtenberg. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Clinical Cancer Research, BMJ Open and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.